Immutep Ltd has released a press release.
TACTI-003 data selected for oral presentation at ESMO 2024
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Story so far
Earlier from Immutep
- First Participant Dosed in Phase I Study of IMP761
- Successful Meeting with FDA on Phase III Design in NSCLC
- Regulatory Clearance received for Phase 1 trial of IMP761
- Webcast to discuss data presented at ESMO Plenary Session
- Positive results in TACTI-003 for 1L HNSCC cohort B patients
Later from Immutep
- Appendix 4E & 2024 Full Year Statutory Accounts
- S&P DJI Announces September 2024 Quarterly Rebalance
- New Positive Efficacy Data for Efti in Head and Neck Cancer
- Immutep receives A$3.6 million French R&D Tax Incentive
- Enrolment for Ph II AIPAC-003 Breast Cancer Trial Completed
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep